by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
7/8/2024
July 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Fed holds interest rates steady, but a cut is expected in coming months; NBI added 7 %
Buysiders and bankers are optimistic headed into 3Q24, as markets are rewarding positive catalysts. But uncertainty over the Fed’s timing on interest rate cuts is keeping a lid on how far the optimism can extend. Fed maintained rates steady, a cut is expected in coming months and NBI added 7 %.
Antibody-Drug Conjugates
Padcev plus Keytruda received positive CHMP opinion for first-line bladder cancer tretment
Astellas announced that EMA’s CHMP has adopted a positive opinion recommending approval of Padcev in combination with Keytruda for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.
Interleukin-15 and Interleukin-2
Innovent presented Phase 1 data of its PD-1/IL-2α-bias bispecific antibody fusion protein
Egle Therapeutics, a biotech company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto- immunity, will deliver an oral presentation at The Promise of Interleukin-2 Therapy meeting taking place in Paris.
Cell Therapies
Carvykti achieved statistically significant improvement in OS in CARTITUDE-4
Johnson & Johnson announced positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating Carvykti (cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
Sdílet na sociálních sítích